Bio-Rad Expands Portfolio of Anti-Idiotypic Antibodies
Bio-Rad has expanded its range of recombinant monoclonal anti-idiotypic antibodies.
Bio-Rad Laboratories recently expanded its portfolio of recombinant monoclonal anti-idiotypic antibodies to include antibodies that are specific to Adcetris (brentuximab vedotin), Cosentyx (secukinumab), and the secukinumab-interleukin 17A (IL-17A) drug-target complex.
Brentuximab vedotin is an antibody drug conjugate used to treat Hodgkin lymphoma, while secukinumab is used to inhibit inflammatory response in several diseases, such as ankylosing spondylitis, psoriasis, and psoriatic arthritis.
According to a company press release from July 12, 2022, these antibodies can be used in the bioanalysis and drug monitoring of brentuximab vedotin, secukinumab, and their biosimilars.
The antibodies for antibrentuximab vedotin and antisecukinumab are approved for in-vitro research purposes, commercial in-vitro testing services to support drug and biosimilar development, and patient monitoring.
Source: Bio-Rad
Psilera, Hesperos Agree to Accelerate Organ-on-a-Chip Treatment for Frontotemporal Dementia
June 9th 2025The partnership leverages the Hesperos organ-on-a-chip platform in the preclinical development of Psilera’s lead compound targeting the progressive neurological disorder for which treatment options are few.
